Physician profile
Ross B Nelson
NPI 1275526592
$1,752.90
in general payments reported to CMS, 2019-2025
21 companies · $507 in 2025
The $507 reported for 2025 was more than what a typical Pain Medicine (Anesthesiology) provider received nationally (typical 2025 total: $458).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $324 · 2020: $33.56 · 2021: $11.28 · 2022: $313 · 2023: $287 · 2024: $278 · 2025: $507.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,071.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,071.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $889.03 | 2022-2025 | Relistor |
| Biodelivery Sciences International, INC. | $151.79 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $102.70 | 2019-2020 | |
| Averitas Pharma INC. | $99.53 | 2024-2025 | Qutenza |
| Curonix LLC | $76.54 | 2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Nevro Corp. | $59.48 | 2024 | Senza |
| Collegium Pharmaceutical, INC. | $48.28 | 2019-2020 | |
| Vertex Pharmaceuticals Incorporated | $47.25 | 2024-2025 | |
| Idorsia Pharmaceuticals US INC | $38.04 | 2023 | Quviviq |
| Scilex Pharmaceuticals INC. | $37.72 | 2019-2022 | |
| Abbott Laboratories | $36.12 | 2025 | Eterna |
| Globus Medical, INC. | $30.38 | 2025 | Senza |
| Tonix Medicines, INC. | $18.90 | 2025 | Tonmya |
| Phathom Pharmaceuticals, INC. | $18.68 | 2025 | Voquezna |
| Convatec INC. | $17.01 | 2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $14.68 | 2024 | |
| Stimwave Technologies Incorporated | $14.50 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.94 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $13.53 | 2023 | Seglentis |
| Stryker Corporation | $12.52 | 2019 | |
| Assertio Therapeutics, INC. | $12.28 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ross Nelson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.